Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | GAK | O14976 | 2/20 | 0.32 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.32 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.32 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | LOX | P28300 | 1/20 | 0.30 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24845804 | 0.83 | MAOA (0.33) | MAOAGAKRIPK2COQ8ANLK | |
| SCHEMBL28048293 | 0.78 | PTK2 (0.36) | MAOANOS3NOS1NOS2GAK | |
| SCHEMBL21713631 | 0.75 | NOS3 (0.34) | MAOANOS3NOS1NOS2 | |
| SCHEMBL28163267 | 0.75 | NOS2 (0.39) | MAOANOS3NOS1NOS2GAK | |
| SCHEMBL30608512 | 0.74 | MAOA (0.37) | MAOANOS3NOS1NOS2GAK | |
| SCHEMBL17563549 | 0.72 | MAOA (0.48) | MAOANOS3NOS1NOS2GAK | |
| SCHEMBL15918749 | 0.71 | MAOA (0.35) | MAOANOS3NOS1NOS2GAK | |
| SCHEMBL15112982 | 0.71 | MAOA (0.35) | MAOANOS3NOS1NOS2GAK | |
| SCHEMBL31103860 | 0.71 | LOXL2 (0.31) | MAOALOXL2 | |
| SCHEMBL741028 | 0.71 | GOT1 (0.33) | MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163078-A1 | IMIDAZOPYRIDAZINE DERIVATIVE, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2025-05-22 | — | — | US | disclosed |
| EP-4484433-A1 | IMIDAZOPYRIDAZINE DERIVATIVE, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2025-01-01 | — | — | EP | disclosed |
| CN-116693555-A | Imidazopyridazine derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2023-09-05 | — | — | CN | disclosed |
| WO-2023160475-A1 | IMIDAZOPYRIDAZINE DERIVATIVE, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2023-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163078-A1 | IMIDAZOPYRIDAZINE DERIVATIVE, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | CYP4A11, CYP4F11, SLC6A11 | MAOA 1410/4885NOS3 3201/4885NOS1 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.